Lanifibranor
- Generic Name
- Lanifibranor
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H15ClN2O4S2
- CAS Number
- 927961-18-0
- Unique Ingredient Identifier
- 28Q8AG0PYL
- Background
Lanifibranor is under investigation in clinical trial NCT03008070 (Phase 2b Study in NASH to Assess IVA337).
- Associated Conditions
- -
- Associated Therapies
- -
A Pharmacokinetic Study of Lanifibranor in Healthy Adult Chinese Subjects
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-01-02
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06126562
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
Multiple Ascending Dose Phase I Study in Order to Define Lanifibranor (IVA337) Supra-thjerapeutic Dose
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- Inventiva Pharma
- Target Recruit Count
- 36
- Registration Number
- NCT03866369
- Locations
- 🇩🇪
Parexel International GmbH, Berlin, Germany
Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-03-08
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 128
- Registration Number
- NCT03459079
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath